OnKure Therapeutics (OKUR) Other Non-Current Assets (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Other Non-Current Assets came in at $405000.0 in Q1 2026, up 271.56% YoY from $109000.0 in Q1 2025, and up 48.35% on a QoQ basis from $273000.0 in Q4 2025.
OnKure Therapeutics (OKUR) Other Non-Current Assets (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Other Non-Current Assets data on file, last reported at $405000.0 in Q1 2026.
- Quarterly Other Non-Current Assets rose 271.56% year-over-year to $405000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $405000.0 (up 271.56% YoY) and the FY2025 annual result came in at $273000.0, up 150.46% from the prior year.
- Other Non-Current Assets rose to $405000.0 in Q1 2026, from $273000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $405000.0 in Q1 2026 to a low of $58000.0 in Q4 2023.
- A 5-year average of $123411.8 and a median of $84000.0 in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets sank 95.36% — and 2026, when it surged 271.56%.
- Tracing OKUR's Other Non-Current Assets over 5 years: stood at $84000.0 in 2022, then plunged by 30.95% to $58000.0 in 2023, then surged by 87.93% to $109000.0 in 2024, then soared by 150.46% to $273000.0 in 2025, then soared by 48.35% to $405000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $405000.0 (Q1 2026), $273000.0 (Q4 2025), and $104000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | OnKure Therapeutics | 195.74 Mn | 19.35 Mn | - | 401,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 401,000.00 |
| Mar 31, 2026 | 405,000.00 |
| Dec 31, 2025 | 273,000.00 |
| Sep 30, 2025 | 104,000.00 |
| Jun 30, 2025 | 116,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Dec 31, 2024 | 109,000.00 |
| Sep 30, 2024 | 147,000.00 |
| Jun 30, 2024 | 153,000.00 |
| Mar 31, 2024 | 64,000.00 |
| Dec 31, 2023 | 58,000.00 |
| Sep 30, 2023 | 81,000.00 |
| Jun 30, 2023 | 79,000.00 |
| Mar 31, 2023 | 81,000.00 |
| Dec 31, 2022 | 84,000.00 |
| Sep 30, 2022 | 79,000.00 |
| Jun 30, 2022 | 78,000.00 |
| Mar 31, 2022 | 78,000.00 |
| Dec 31, 2021 | 78,000.00 |
| Sep 30, 2021 | 78,000.00 |